Health, Fitness & Food

Suriyapong Thongsawang | Moment | Getty Images Doctors in the U.S. are struggling to contend with burnout, staffing shortages and overwhelming administrative workloads, but many are optimistic that artificial intelligence could help to ease these problems, a new survey found.  More than 90% of physicians report feeling burned out on a “regular basis,” according to
0 Comments
In this article BIIB Follow your favorite stocksCREATE FREE ACCOUNT Eisai | via Reuters Good afternoon! The launch of the closely watched Alzheimer’s drug Leqembi is off to a slow start. Still, demand for the treatment from Biogen and its Japanese partner Eisai is rising. That’s the update the two drugmakers gave Wall Street during their
0 Comments
In this article ABBV Follow your favorite stocksCREATE FREE ACCOUNT Test tubes are seen in front of a displayed AbbVie logo in this illustration taken on May 21, 2021. Dado Ruvic | Reuters AbbVie on Tuesday said longtime executive Robert Michael will become the company’s new CEO, replacing Richard Gonzalez.  Michael, who is AbbVie’s president
0 Comments
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023.  Brendan Mcdermid | Reuters Many U.S. companies are grappling with health insurance coverage issues for workers when it comes to GLP-1 drugs for weight loss. Despite the hefty price tag — typically between $1,000 to
0 Comments
In this article BIIB Follow your favorite stocksCREATE FREE ACCOUNT A Biogen facility in Cambridge, Massachusetts. Brian Snyder | Reuters Biogen on Tuesday reported fourth-quarter revenue and profit that shrank from a year ago, as it recorded charges related to dropping its controversial Alzheimer’s drug Aduhelm and as sales slumped in its multiple sclerosis therapies, the
0 Comments
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Tuesday’s key moments. 1. U.S. stocks tumbled Tuesday on hotter-than-expected retail inflation data. The surprise uptick in the January consumer price index sent bond yields higher and the Dow , the S &
0 Comments
In this article FTCI Follow your favorite stocksCREATE FREE ACCOUNT A variety of generic pills and capsules.  Nenov | Moment | Getty Images The Federal Trade Commission on Wednesday said it is examining the role that drug wholesalers and companies that purchase medicines for U.S. health-care providers play in shortages of generic drugs, which account
0 Comments
Activists protest the price of prescription drug costs in front of the U.S. Department of Health and Human Services (HHS) building on October 06, 2022 in Washington, DC. Anna Moneymaker | Getty Images A federal judge on Monday tossed a lawsuit brought by a major pharmaceutical industry lobbying group and two other organizations, which challenged
0 Comments
US Defense Secretary Lloyd Austin takes questions during a press conference at the Pentagon in Washington, DC, on February 1, 2024.  Andrew Caballero-reynolds | Afp | Getty Images Defense Secretary Lloyd Austin was taken back to the hospital on Sunday afternoon for symptoms related to a possible bladder issue, the Pentagon announced. Austin is battling
0 Comments
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Tuesday’s key moments. 1. U.S. stocks were mixed Tuesday, on a muted performance from Big Tech. Citigroup strategists warned that tech stocks may stall out after monstrous gains. “The large consensus positioning is
0 Comments
In this article NVO NOVO.B-DK LLY Follow your favorite stocksCREATE FREE ACCOUNT Injection pens of Novo Nordisk’s weight-loss drug Wegovy are shown in this photo illustration in Oslo, Norway, Nov. 21, 2023. Victoria Klesty | Reuters The insatiable demand for weight loss drugs is trouncing supply, leaving many patients struggling to find the injectable treatments. 
0 Comments
Good afternoon! All eyes are on Novo Nordisk and Eli Lilly again as Wall Street looks for signs that they can address one of the biggest hurdles they faced last year. Neither company has enough supply to meet the insatiable demand for their weight loss and diabetes drugs.  One month into 2024, the two drugmakers still haven’t fully resolved those supply issues.
0 Comments